Encyclopedia of contested claims
Clinical trial evidence indicates that semaglutide can produce substantial weight loss while treatment continues, especially at the higher dose marketed for weight management. Weight regain is commonly reported after stopping the medication, so “sustained” weight loss depends strongly on continued treatment and accompanying lifestyle support.
9 reviewing models concluded the claim is not supported by the available evidence.
The Adjudged panel has not yet completed its full review of this claim. This draft summarizes the main lines of publicly available evidence for orientation and identifies the key questions the panel would examine before issuing a final assessment.
Clinical trial evidence indicates that semaglutide can produce substantial weight loss while treatment continues, especially at the higher dose marketed for weight management. Weight regain is commonly reported after stopping the medication, so “sustained” weight loss depends strongly on continued treatment and accompanying lifestyle support.
The claim asks whether Ozempic, or semaglutide more broadly, causes sustained weight loss. Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes under the Ozempic brand and for chronic weight management under the Wegovy brand. The same active drug is involved, but the approved dose, indication, and trial populations differ.
For this article, the central question is not only whether people lose weight while taking semaglutide, but whether that weight loss persists over time. That matters because many weight-loss interventions show short-term effects that may diminish after treatment stops or as adherence changes.
A careful judgment should separate several related issues: weight loss during active treatment, maintenance of weight loss during longer-term treatment, and weight regain after discontinuation. It should also distinguish average effects in trials from what an individual patient may experience.
Randomized clinical trials of semaglutide for weight management have reported large average reductions in body weight compared with placebo when the medication is taken alongside lifestyle intervention. In the STEP 1 trial, adults with overweight or obesity who received once-weekly semaglutide 2.4 mg had a markedly greater average percentage weight loss over 68 weeks than those receiving placebo.
Longer follow-up also supports maintenance of weight loss during continued treatment. In STEP 5, semaglutide 2.4 mg was associated with substantial average weight reduction over two years compared with placebo, suggesting that the effect can persist while therapy is maintained.
However, withdrawal studies show that stopping semaglutide is commonly followed by weight regain. An extension of STEP 1 reported that participants regained a meaningful portion of the weight they had lost after treatment and lifestyle intervention were discontinued. This pattern supports viewing semaglutide as a chronic-treatment option for many patients rather than a short course with permanently maintained effects.
The evidence is strongest for semaglutide 2.4 mg, the dose studied and approved for chronic weight management, rather than lower Ozempic doses used primarily for diabetes. People using Ozempic may lose weight, but weight outcomes can vary by dose, diagnosis, baseline weight, diet, physical activity, side effects, and duration of treatment.
The biggest uncertainty for everyday readers is what “sustained” should mean. If it means weight loss maintained during ongoing treatment, the trial evidence is supportive. If it means weight loss maintained after stopping semaglutide, available evidence suggests many people regain weight.
There are also open questions about very long-term use beyond the main trial periods, real-world adherence, cost and access, side-effect-related discontinuation, and outcomes in populations underrepresented in trials. Real-world results may be less uniform than trial results because patients differ in medical history, dose titration, lifestyle support, and ability to keep taking the drug.
Any final assessment should also weigh benefits against risks and practical considerations. Common adverse effects include gastrointestinal symptoms, and semaglutide is not appropriate for every patient. Medical decisions should be made with a qualified clinician who can evaluate individual risks, contraindications, and treatment goals.
The umbrella claim is actually several claims bundled into one. Each needs its own evaluation.
| Model | Part 1 | Part 2 | Part 3 | Overall |
|---|---|---|---|---|
| Grok 4.3 | No · 92% | No · 84% | No · 82% | No · 90% |
| Mistral Medium 3.5 | No · 92% | No · 84% | No · 82% | No · 90% |
| Llama 4 Maverick | No · 92% | No · 84% | No · 82% | No · 90% |
| OpenAI GPT-5.4 | No · 92% | No · 84% | No · 82% | No · 90% |
| Gemini 3.1 Pro | No · 92% | No · 84% | No · 82% | No · 90% |
| Claude Opus 4.7 | No · 92% | No · 84% | No · 82% | No · 90% |
| GLM 5.1 | No · 92% | No · 84% | No · 82% | No · 90% |
| DeepSeek V4 Pro | No · 92% | No · 84% | No · 82% | No · 90% |
| Qwen 3.7 Max | No · 92% | No · 84% | No · 82% | No · 90% |
| Kimi K2.6 | — | — | — | Incomplete |
The current evidence leans one way. But we're not committed to the conclusion, we're committed to the evidence.
Semaglutide produces substantial average weight loss (typically 10-15% or more) versus placebo during active treatment in adults with overweight or obesity, and this can be maintained for at least two years wit...
Semaglutide (including Ozempic at lower doses and Wegovy at 2.4 mg) does cause significant weight loss during active treatment, but "sustained" weight loss is contingent on continued use. The claim is partially...
Semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for weight management, can cause substantial weight loss during treatment, particularly at the higher dose of 2.4 mg used for weight management. T...
Mostly yes during ongoing treatment, but not reliably after stopping. I’d judge the overall claim as supported with an important qualification: semaglutide produces clinically meaningful weight loss that can be sustained for years if treatment continues, but evidence does not support that most patients keep all of that weight loss once the drug is discontinued. Confidence: high. Key evidence: - Active treatment works better than placebo. In the pivotal STEP 1 randomized trial in adults with overweight/obesity witho...
Semaglutide (marketed as Ozempic for type 2 diabetes and Wegovy for weight management) causes sustained weight loss only if the patient continues taking the medication; it does not permanently alter body weight...
Semaglutide produces substantial weight loss during treatment, but that loss is largely contingent on continued use — it is not "sustained" in the sense of persisting after discontinuation for most patients. Co...
Semaglutide causes sustained weight loss only while treatment continues; weight loss is not sustained after stopping the medication. Confidence: High. Key evidence: The STEP 1 trial (NEJM) established that sema...
Semaglutide (the active ingredient in Ozempic and Wegovy) does not cause sustained weight loss that persists after treatment is stopped. Clinical trials demonstrate that the medication produces significant weig...
Semaglutide (the active ingredient in Ozempic and Wegovy) produces substantial weight loss that is sustained only as long as the medication is continuously taken; it does not result in permanent weight loss aft...
